CLAIMS

1. A composition comprising:

an effective amount of rifabutin;

an effective amount of clarithromycin; and

an effective amount of clofazimine,

wherein the effective amounts of rifabutin, clarithromycin, and clofazimine are sufficient to enable treatment of a subject suffering from an autoimmune disease by targeting cytokines or cytokine receptors.

2. The composition of claim 1 further comprising an antibiotic selected from the group consisting of daptomycin, clindamycin, rifampicin, erythromycin, oleandomycin, roxithromycin, azithromycin, kanamycin, gentamycin, tobramycin, streptomycin, neomycin, paromomycin, ethambutol, isoniazid, minocyclin, and tetracycline.

3. The composition of claim 1 wherein the autoimmune disease is a disease of the central nervous system.

4. The composition of claim 1 wherein the autoimmune disease is multiple sclerosis.

5. The composition of claim 1 wherein the autoimmune disease is Hashimoto's Thyroiditis, Melkersson-Rosenthal syndrome or Sarcoidosis.

6. The composition of claim 1 formulated for oral administration.

7. The composition of claim 1 formulated for intravenous administration.

8. The composition of claim 1 wherein the clofazimine is dispersed in an absorption enhancer.

9. The composition of claim 8 wherein the absorption enhancer is polyethylene glycol.

10. The composition of claim 1 further comprising an anti-inflammatory agent selected from one or a combination of 5-aminosalicylic acid, azathioprine or methotrexate.

11. Use of an effective amount of rifabutin, clarithromycin, and clofazimine in the preparation of a medicament for the therapeutic and/or prophylactic treatment of an autoimmune disease that is characterized by an increase in cytokines.

CLAIMS

1. A composition comprising:
   an effective amount of rifabutin;
   an effective amount of clarithromycin; and
   an effective amount of clofazimine,
for use in the treatment of multiple sclerosis.

2. The composition of claim 1 further comprising an antibiotic selected from the group consisting of daptomycin, clindamycin, rifampicin, erythromycin, oleandomycin, roxithromycin, azithromycin, kanamycin, gentamycin, tobramycin, streptomycin, neomycin, paromomycin, ethambutol, isoniazid, minocyclin, and tetracycline.

3. The composition of claim 1 formulated for oral administration.

4. The composition of claim 1 formulated for intravenous administration.

5. The composition of claim 1 further comprising an absorption enhancer.

6. The composition of claim 1 wherein the clofazimine is dispersed in polyethylene glycol.

7. The composition of claim 1 further comprising an anti-inflammatory agent.

8. Use of an effective amount of rifabutin, clarithromycin, and clofazimine in the preparation of a medicament for the therapeutic and/or prophylactic treatment of multiple sclerosis.

9. The composition of claim 1 for the treatment of remitting-relapsing multiple sclerosis.

10. The composition of claim 1 further comprising Vitamin D.

11. The composition of claim 1 further comprising a cyclin dependent kinase inhibitor.

12. The composition of claim 1 further comprising an activated T-cell transcription inhibitor.

13. The composition of claim 1 wherein, upon administration of the composition to a subject with multiple sclerosis, a reduction in demyelination is observed.

14. The composition of claim 1 wherein, upon administration of the composition to a subject with multiple sclerosis, at least an amelioration of one or more symptoms associated with multiple sclerosis is observable.

15. The composition of claim 7 wherein the anti-inflammatory agent is selected from one or a combination of 5-aminosalicylic acid, azathioprine or methotrexate.